Efficacy Evaluation of Metoprolol Succinate Sustained Release Tablets Combined with Trimetazidine in the Treatment of Angina Pectoris of Coronary Heart Disease
Objective To explore the clinical value of metoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of angina pectoris of coronary atherosclerotic heart disease(CHD).Methods A total of 66 patients with angina pectoris of CHD admitted to Shandong Guoxin Yiyang Group Zaozhuang Central Hospital from January 2022 to August 2023 were conveniently selected as the research objects,and were divided into two groups by coin tossing method.The reference group(33 cases)was treated with metoprolol succinate sustained-release tablets.The study group(33 cases)was treated with trimetazidine on the basis of the reference group.The improvement of an-gina pectoris,the occurrence of adverse reactions,the level of cardiac function index,the score of angina pectoris symptoms and the therapeutic effect were compared between the two groups.Results After treatment,the improvement of angina pectoris,cardiac function index and angina pectoris symptom score in the study group were better than those in the reference group,and the differences were statistically significant(all P<0.05).The incidence of adverse reac-tions in the study group was lower than that in the reference group,the difference was statistically significant(P<0.05).The effective rate of treatment in the study group(96.97%)was higher than that in the reference group(78.79%),and the difference was statistically significant(χ2=5.120,P<0.05).Conclusion Reasonable selection of metoprolol succi-nate sustained-release tablets+trimetazidine in the treatment of angina pectoris of coronary heart disease can im-prove the symptoms of patients,improve the therapeutic effect and safety.
万方数据
维普
